Dystrophin expression in the <i>mdx</i> mouse after localised and systemic administration of a morpholino antisense oligonucleotide

Abstract

The stability of the morpholino structural type, and the fact that it can be delivered to muscle in the absence of a delivery reagent, render this compound eminently suitable for consideration for therapeutic exon skipping to address dystrophin mutations.